vs
Side-by-side financial comparison of BioNexus Gene Lab Corp (BGLC) and Celcuity Inc. (CELC). Click either name above to swap in a different company.
BioNexus Gene Lab Corp is a biotechnology company specializing in molecular diagnostic testing, genetic analysis, and related life science solutions. It caters to healthcare institutions, research organizations, and individual customers, with its primary operational and market focus on the Southeast Asian region.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $483.8K | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $2.3M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $2.6M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $2.4M | — |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-709.0K | — | ||
| Q2 25 | $-616.2K | — | ||
| Q1 25 | $-623.3K | — | ||
| Q4 24 | $-348.3K | — | ||
| Q3 24 | $-1.3M | — | ||
| Q2 24 | $199.1K | — | ||
| Q1 24 | $-103.8K | — |
| Q4 25 | -0.8% | — | ||
| Q3 25 | 14.8% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 16.1% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 15.3% | — |
| Q4 25 | -213.5% | — | ||
| Q3 25 | -27.6% | — | ||
| Q2 25 | -27.0% | — | ||
| Q1 25 | -28.9% | — | ||
| Q4 24 | -16.5% | — | ||
| Q3 24 | -50.9% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | -3.3% | — |
| Q4 25 | -214.2% | — | ||
| Q3 25 | -27.9% | — | ||
| Q2 25 | -27.3% | — | ||
| Q1 25 | -29.2% | — | ||
| Q4 24 | -13.8% | — | ||
| Q3 24 | -51.1% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | -4.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.40 | — | ||
| Q2 25 | $-0.34 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $-0.75 | — | ||
| Q2 24 | $0.11 | — | ||
| Q1 24 | $-0.01 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
